What is Upheal?
Upheal operates at the intersection of artificial intelligence and behavioral health, providing a specialized platform designed to optimize the clinical experience. By integrating seamlessly into the daily operations of therapists, the company effectively reduces the time spent on non-clinical administrative tasks. This focus on workflow automation not only enhances operational efficiency for individual practitioners but also scales to meet the needs of larger clinical organizations. As the mental health industry faces increasing pressure to manage higher patient volumes, Upheal's technology acts as a force multiplier for clinicians, allowing them to prioritize patient interaction over manual documentation.
How much funding has Upheal raised?
Upheal has raised a total of $14.3M across 3 funding rounds:
Other Financing Round
$1M
Angel/Seed
$3.3M
Series A
$10M
Other Financing Round (2022): $1M with participation from Kaya Vc, Calm/Storm Ventures, Juraj Masar, and Credoventures
Angel/Seed (2024): $3.3M led by Inovia, Credoventures, and Kaya Vc
Series A (2024): $10M supported by Credoventures, Kaya Ventures, and Headline
Key Investors in Upheal
Credoventures
A venture capital fund supporting ambitious founders from Central and Eastern Europe, focusing on early-stage investments and fostering generational companies.
Kaya Ventures
A thesis-driven investment firm dedicated to advancing healthcare innovation, with a specific focus on digital health and the care economy.
Headline
A global venture capital firm that partners with fast-growing technology teams, leveraging its international presence to lead rounds at every stage of growth.
What's next for Upheal?
With the successful closure of this major strategic investment, Upheal is well-positioned to accelerate its product development roadmap and expand its footprint in the global HealthTech market. The company is expected to leverage this capital to enhance its AI capabilities, potentially introducing more sophisticated diagnostic support tools and deeper integration with electronic health record systems. Furthermore, the involvement of high-profile venture capital partners suggests a strategic push toward scaling operations and solidifying its competitive advantage in the European and North American markets. As the company transitions into this next phase of growth, the focus will likely shift toward enterprise-wide adoption and the establishment of new standards for AI-assisted mental health care.
See full Upheal company page
